Thrivent Financial for Lutherans Raises Holdings in Inogen (INGN)

Thrivent Financial for Lutherans grew its position in shares of Inogen (NASDAQ:INGN) by 1.8% during the 1st quarter, according to the company in its most recent disclosure with the SEC. The fund owned 138,747 shares of the medical technology company’s stock after purchasing an additional 2,419 shares during the quarter. Thrivent Financial for Lutherans owned approximately 0.65% of Inogen worth $17,044,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently modified their holdings of INGN. Louisiana State Employees Retirement System grew its holdings in shares of Inogen by 7.2% during the fourth quarter. Louisiana State Employees Retirement System now owns 7,400 shares of the medical technology company’s stock worth $881,000 after purchasing an additional 500 shares during the last quarter. Schwab Charles Investment Management Inc. grew its holdings in shares of Inogen by 3.0% during the fourth quarter. Schwab Charles Investment Management Inc. now owns 79,600 shares of the medical technology company’s stock worth $9,479,000 after purchasing an additional 2,327 shares during the last quarter. Acadian Asset Management LLC grew its holdings in shares of Inogen by 31.5% during the fourth quarter. Acadian Asset Management LLC now owns 6,980 shares of the medical technology company’s stock worth $832,000 after purchasing an additional 1,674 shares during the last quarter. Steward Partners Investment Advisory LLC grew its holdings in shares of Inogen by 1,000.0% during the fourth quarter. Steward Partners Investment Advisory LLC now owns 1,100 shares of the medical technology company’s stock worth $130,000 after purchasing an additional 1,000 shares during the last quarter. Finally, Sumitomo Mitsui Asset Management Company LTD purchased a new position in shares of Inogen during the fourth quarter worth about $1,776,000. 99.40% of the stock is currently owned by institutional investors.

NASDAQ INGN opened at $187.76 on Friday. Inogen has a 52-week low of $81.85 and a 52-week high of $188.45. The stock has a market cap of $3.98 billion, a P/E ratio of 125.17, a P/E/G ratio of 4.75 and a beta of 1.01.

Inogen (NASDAQ:INGN) last released its quarterly earnings results on Monday, April 30th. The medical technology company reported $0.48 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.29 by $0.19. Inogen had a return on equity of 14.81% and a net margin of 9.36%. The firm had revenue of $79.05 million for the quarter, compared to analyst estimates of $63.86 million. During the same quarter last year, the company posted $0.27 earnings per share. The business’s revenue was up 50.6% on a year-over-year basis. analysts expect that Inogen will post 1.76 EPS for the current year.

In related news, Director Loren L. Mcfarland sold 2,125 shares of the firm’s stock in a transaction dated Friday, May 11th. The stock was sold at an average price of $181.44, for a total transaction of $385,560.00. Following the transaction, the director now owns 3,114 shares of the company’s stock, valued at $565,004.16. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Scott Wilkinson sold 9,198 shares of the firm’s stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $170.35, for a total value of $1,566,879.30. The disclosure for this sale can be found here. In the last three months, insiders have sold 49,148 shares of company stock worth $6,778,955. Corporate insiders own 5.29% of the company’s stock.

INGN has been the topic of several research reports. Zacks Investment Research raised Inogen from a “hold” rating to a “buy” rating and set a $132.00 price objective on the stock in a report on Tuesday, February 6th. Piper Jaffray raised Inogen from a “neutral” rating to an “overweight” rating in a report on Tuesday, February 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $150.00 price objective on shares of Inogen in a report on Tuesday, March 27th. ValuEngine raised Inogen from a “hold” rating to a “buy” rating in a report on Friday, April 6th. Finally, BidaskClub raised Inogen from a “buy” rating to a “strong-buy” rating in a report on Friday, April 6th. One analyst has rated the stock with a hold rating, three have assigned a buy rating and three have assigned a strong buy rating to the stock. Inogen has a consensus rating of “Buy” and an average price target of $178.00.

Inogen Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Institutional Ownership by Quarter for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply